Jakafi is a medication used to treat certain blood cancers. While specific sales figures for October 28, 2025, are not publicly available in advance, general sales trends and patent information can be discussed.
How is Jakafi performing financially?
Jakafi, also known by its generic name ruxolitinib, has demonstrated significant commercial success. In the first quarter of 2024, net sales of Jakafi reached $645 million, marking a 7% increase compared to the same period in 2023 [1]. This growth indicates sustained demand for the drug in its approved indications [1].
When does Jakafi's patent protection end?
The patent landscape for Jakafi is complex, with various patents covering different aspects of the drug, including its composition of matter and methods of use [2]. While specific expiry dates for all patents are not readily available, the primary patents for ruxolitinib began to expire around 2027-2028 [3]. This timeline is crucial for understanding potential market entry of generic versions.
Could generic versions of Jakafi be available soon?
The expiration of key patents opens the door for generic manufacturers to seek approval for their versions of ruxolitinib. Regulatory bodies like the U.S. Food and Drug Administration (FDA) review abbreviated new drug applications (ANDAs) for generics [4]. The availability of generic alternatives typically leads to price reductions and increased market competition.
What are the approved uses for Jakafi?
Jakafi is indicated for the treatment of several myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD). In the U.S., it is approved for:
* Myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF [5].
* Polycythemia Vera (PV) in patients who have had an inadequate response to or are intolerant of hydroxyurea [5].
* Acute GVHD after failure of corticosteroids [5].
* Chronic GVHD after failure of at least one prior systemic therapy [5].
Are there other JAK inhibitors on the market?
Yes, other Janus kinase (JAK) inhibitors are available for treating MPNs and related conditions. These include medications such as Incyte's Opzelura (ruxolitinib) for atopic dermatitis, which is a different formulation of the same active ingredient but for a distinct indication [1]. Additionally, other JAK inhibitors are approved for various hematologic malignancies and inflammatory conditions, each with its own efficacy, safety profile, and patent status.
What are the risks associated with Jakafi?
Jakafi carries a boxed warning regarding serious and potentially fatal adverse reactions, including thrombosis, cardiovascular death, myocardial infarction, stroke, and other thromboembolic events [5]. It can also cause serious infections and an increased risk of mortality in patients with myelosuppression [5]. Other significant risks include hematologic toxicities, impaired healing, and the potential development of certain cancers, such as non-melanoma skin cancer and lymphoma [5].
Sources:
1. https://drugpatentwatch.com/companies/incyte
2. https://drugpatentwatch.com/drugs/jakafi
3. https://drugpatentwatch.com/search/ruxolitinib
4. https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas-generics
5. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/jakafi-ruxolitinib-risk-evaluation-and-mitigation-strategy-rems